EdgeMarket › What Parkman Healthcare Partners Llc reported owning
What Parkman Healthcare Partners Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
969.6MPositions
90Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| SYK STRYKER CORP | 50.9M | 5.2% | 154.8K | 329.45 | -15.9% |
| DXCM DEXCOM INC | 43.3M | 4.5% | 689.8K | 92.34 | +13.1% |
| unmapped CUSIP 483497103 | 36.9M | 3.8% | 1.8M | — | — |
| PODD INSULET CORP | 32.9M | 3.4% | 156.6K | 148.16 | -55.5% |
| LLY ELI LILLY & Co | 31.8M | 3.3% | 34.6K | 1,255.40 | +78.0% |
| PTCT PTC THERAPEUTICS, INC. | 29.4M | 3.0% | 431.4K | 69.82 | +42.9% |
| XENE Xenon Pharmaceuticals Inc. | 28.9M | 3.0% | 497.0K | 60.77 | +61.5% |
| BSX BOSTON SCIENTIFIC CORP | 28.2M | 2.9% | 448.8K | 50.37 | -52.5% |
| CVS CVS HEALTH Corp | 27.8M | 2.9% | 387.3K | 93.02 | +31.3% |
| RCUS Arcus Biosciences, Inc. | 26.1M | 2.7% | 1.2M | 30.34 | +200.7% |
| LIVN LivaNova PLC | 25.7M | 2.6% | 404.0K | 78.74 | +47.5% |
| ZBH ZIMMER BIOMET HOLDINGS, INC. | 24.4M | 2.5% | 269.6K | 100.98 | -4.5% |
| MBX MBX Biosciences, Inc. | 23.9M | 2.5% | 800.0K | 66.33 | +386.6% |
| ANIP ANI PHARMACEUTICALS INC | 21.6M | 2.2% | 280.6K | 75.35 | -16.9% |
| SNDX Syndax Pharmaceuticals Inc | 21.1M | 2.2% | 901.5K | 19.65 | +24.8% |
| QGEN QIAGEN N.V. | 20.0M | 2.1% | 500.0K | 44.07 | -10.4% |
| NVST Envista Holdings Corp | 18.1M | 1.9% | 711.7K | 27.20 | +31.3% |
| EYPT EyePoint, Inc. | 17.5M | 1.8% | 1.4M | 5.32 | -53.8% |
| ABBV AbbVie Inc. | 16.3M | 1.7% | 75.0K | 264.96 | +26.7% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 16.3M | 1.7% | 1.7M | 9.55 | +14.0% |
| IQV IQVIA HOLDINGS INC. | 14.8M | 1.5% | 86.7K | 259.82 | +35.3% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 13.7M | 1.4% | 403.5K | 33.09 | -10.1% |
| ILMN ILLUMINA, INC. | 13.6M | 1.4% | 110.4K | 219.40 | +117.7% |
| EW Edwards Lifesciences Corp | 13.4M | 1.4% | 167.2K | 89.79 | +10.3% |
| NBIX NEUROCRINE BIOSCIENCES INC | 13.1M | 1.3% | 99.1K | 152.57 | +14.5% |
| KNSA Kiniksa Pharmaceuticals International, plc | 12.5M | 1.3% | 259.2K | 79.03 | +138.0% |
| ASMB ASSEMBLY BIOSCIENCES, INC. | 11.4M | 1.2% | 411.2K | 34.38 | +31.5% |
| GPCR Structure Therapeutics Inc. | 11.2M | 1.2% | 232.1K | 49.09 | +164.4% |
| MCK MCKESSON CORP | 11.0M | 1.1% | 12.7K | 858.90 | +22.2% |
| STOK Stoke Therapeutics, Inc. | 11.0M | 1.1% | 336.5K | 32.29 | +67.1% |
| VRDN Viridian Therapeutics, Inc.\DE | 10.9M | 1.1% | 557.9K | 24.29 | +33.9% |
| WAY Waystar Holding Corp. | 10.7M | 1.1% | 443.1K | 25.01 | -28.7% |
| MLYS Mineralys Therapeutics, Inc. | 10.3M | 1.1% | 380.1K | 25.65 | +65.7% |
| EWTX Edgewise Therapeutics, Inc. | 10.2M | 1.0% | 322.8K | 44.18 | +219.2% |
| XERS Xeris Biopharma Holdings, Inc. | 10.0M | 1.0% | 1.7M | 8.70 | +14.9% |
| THC TENET HEALTHCARE CORP | 9.5M | 1.0% | 50.1K | 280.77 | +54.3% |
| AORT ARTIVION, INC. | 9.2M | 1.0% | 252.0K | 28.08 | -34.7% |
| unmapped CUSIP 670703107 | 9.0M | 0.9% | 88.1K | — | — |
| ATEC Alphatec Holdings, Inc. | 9.0M | 0.9% | 823.8K | 9.48 | -40.3% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 8.9M | 0.9% | 26.9K | 236.22 | -48.5% |
| AXGN Axogen, Inc. | 8.9M | 0.9% | 268.2K | 50.40 | +223.9% |
| IMNM Immunome Inc. | 8.8M | 0.9% | 403.5K | 28.52 | +198.0% |
| AMLX Amylyx Pharmaceuticals, Inc. | 8.6M | 0.9% | 621.5K | 38.66 | +381.4% |
| IDXX IDEXX LABORATORIES INC /DE | 8.4M | 0.9% | 15.0K | 556.93 | -13.0% |
| WAT WATERS CORP /DE/ | 7.9M | 0.8% | 26.4K | 410.70 | +38.4% |
| ADPT Adaptive Biotechnologies Corp | 7.7M | 0.8% | 551.8K | 25.99 | +111.4% |
| UPB Upstream Bio, Inc. | 7.1M | 0.7% | 786.8K | 6.97 | -57.4% |
| ERAS Erasca, Inc. | 6.6M | 0.7% | 406.7K | 17.63 | +1107.5% |
| APGE Apogee Therapeutics, Inc. | 6.5M | 0.7% | 77.7K | 134.75 | +274.1% |
| COO COOPER COMPANIES, INC. | 6.4M | 0.7% | 89.9K | 76.22 | +3.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →